Αποτελέσματα Αναζήτησης
3 Ιαν 2024 · Dr. Leon Ferre and other researchers at Mayo Clinic are working to understand how triple-negative breast cancer grows and spreads, how the immune system may recognize and fight it, and to develop new treatments for the disease.
19 Ιουν 2023 · •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
15 Σεπ 2024 · The estimated overall survival at 60 months was 86.6% (95% confidence interval [CI], 84.0 to 88.8) in the pembrolizumab–chemotherapy group, as compared with 81.7% (95% CI, 77.5 to 85.2) in the...
25 Απρ 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
11 Ιαν 2022 · High TIL levels are linked to a higher overall survival rate in patients with TNBC. TIL levels can be used as predictive and prognostic markers to assess the effectiveness of different standard therapies, such as neoadjuvant and adjuvant chemotherapy.
14 Αυγ 2024 · The Neo-Real study (GBECAM-0123) is a real-world data effort evaluating patients with TNBC treated with neoadjuvant P + CT in ten cancer centers since July 2020. The objective of this analysis...
